SCHEMBL7122830

SCHEMBL7122830

CCOc1ccc(C2CCC2C(=O)c2cc(OC)c(OC)c(OC)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
POLB P06746 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
TUBB4A P04350 2/20 0.45
TUBB P07437 2/20 0.45
TUBA3C P0DPH7 2/20 0.45
TUBA1B P68363 2/20 0.45
TUBA4A P68366 2/20 0.45
TUBB4B P68371 2/20 0.45
TUBB3 Q13509 2/20 0.45
TUBB2A Q13885 2/20 0.45
TUBB8 Q3ZCM7 2/20 0.45
TUBA3E Q6PEY2 2/20 0.45
TUBA1A Q71U36 2/20 0.45
TUBA1C Q9BQE3 2/20 0.45
TUBB6 Q9BUF5 2/20 0.45
TUBB2B Q9BVA1 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118783 0.93 POLB (0.47) MAPTSMN1; SMN2POLBALDH1A1KDM4E
SCHEMBL6859990 0.92 POLB (0.45) MAPTSMN1; SMN2POLBALDH1A1KDM4E
SCHEMBL7118801 0.92 MAPT (0.50) MAPTSMN1; SMN2POLBALDH1A1KDM4E
SCHEMBL6853080 0.91 POLB (0.46) MAPTSMN1; SMN2POLBALDH1A1KDM4E
SCHEMBL7127059 0.89 TUBB1 (0.54) MAPTPOLBALDH1A1TUBB4ATUBB
SCHEMBL7122702 0.83 TUBB4A (0.47) MAPTPOLBALDH1A1KDM4ETUBB4A
SCHEMBL7118795 0.82 TUBB1 (0.51) MAPTPOLBALDH1A1TUBB4ATUBB
SCHEMBL7123051 0.81 MAPT (0.46) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL7129321 0.81 TUBB4A (0.48) MAPTPOLBALDH1A1KDM4ETUBB4A
SCHEMBL7124632 0.81 ALDH1A1 (0.52) MAPTPOLBALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885SMN1; SMN2 4052/4885POLB 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.